Mylan gains FDA nod for generic migraine therapy

05/17/2013 | Drug Store News

Mylan received federal approval for its zolmitriptan tablets in two strengths, 2.5 mg and 5 mg. The drug, which addresses acute migraine in adults, is a generic form of Zomig by IPR Pharmaceuticals.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI